HeartFlow’s $364M IPO and SetPoint Medical’s $140M financing headline an active week in MedTech funding, highlighting strong interest in transformative therapies. A mix of mid- and early-stage rounds – from Reprieve Cardiovascular to Vivani – demonstrates continued momentum for emerging companies. See the full breakdown in this week’s GS MedTech Funding Tracker.
Heartflow closes upsized $364.2M IPO
Heartflow announced today that it closed its upsized initial public offering (IPO) with proceeds totaling approximately $364.2 million. Last month, the company filed an S-1 registration form with the SEC, signaling its intent to IPO.
Last week, it priced the offering at $19 per share, targeting proceeds of $316.7 million. Shares of HTFL began trading on the Nasdaq market on Friday, Aug. 8, and closed trading today at $29.99 apiece.
President and CEO John Farquhar
Last week’s tracker: HistoSonics, Alcon, and more
Fresenius Medical Care initiates $698.4M buyback tranche
Fresenius Medical Care announced today that it launched the first tranche of a $1.16 billion share buyback. The buyback tranche, which totals about $696 million, comes as part of the company’s new capital allocation framework.
The company expects to complete the tranche by April 30, 2026, at the latest.
CEO Helen Giza
Inspire Medical authorizes $200M share repurchase
Inspire Medical announced today that its board of directors authorized the repurchase of up to $200 million in common stock. The board authorized the repurchase of the Minneapolis-based sleep respiratory therapy maker’s own common stock, with timing, manner, price and amount determined by the company at its discretion.
Purchases can take place through open-market transactions, privately negotiated transactions, transactions structured through investment banking institutions or other means.
Chair and CEO Tim Herbert
SetPoint Medical raises $140m to support its arthritis neuromod implant
SetPoint Medical raised $140 million in private financing, including a second Series C tranche and its Series D round. The financing includes $25 million in the Series C round’s second tranche, followed by $115 million from the Series D.
Elevage Medical Technologies and Ally Bridge Group co-led the financing. The company plans to use proceeds to support commercialisation efforts for its neuroimmune modulation therapy.
CEO Murthy V. Simhambhatla, Ph.D.
Reprieve Cardiovascular raised $61m for heart failure treatment system
Reprieve Cardiovascular closed an oversubscribed Series B financing totaling $61 million. Deerfield Management led the funding round. Arboretum Ventures, Lightstone Ventures, Sante Ventures, Genesis Capital, Rex Health Ventures and Cadence Capital joined with an undisclosed strategic investor.
The financing combined equity investment with a debt facility to support the company’s growth. The company plans to use proceeds to support the execution of its pivotal clinical trial and to support commercial readiness activities. Its FASTR II trial already enrolled its first patient ahead of evaluating the Reprieve system.
CEO Mark Pacyna
Conformal Medical closes $32m Series D extension
Conformal Medical closed a Series D extension financing totaling $32 million in proceeds. The company originally completed its Series D round in 2023, bringing in $35 million.
With a new partner joining inside investors, the company is adding the $32 million to support its heart implant technology. It plans to use funds to support the enrollment of its ongoing CONFORM pivotal trial and fund pre-commercialization initiatives for CLAAS AcuForm.
President and CEO James Reinstein
Vivani closes $10M financing, advances GLP-1 implant
Vivani Medical announced that it brought in $10 million in equity financing as it progresses its drug delivery technology. The company says the funding secures its financial position through the second half of 2026.
It also supports the prioritization and accelerated development of NPM-139, its semaglutide implant, into clinical-stage development, with initiation anticipated in 2026.
CEO Adam Mendelsohn
Healthtech startup Dozee to raise $10 Mn in debt
Healthtech startup Dozee is set to raise $10 million in debt funding from Stockhausen International Pte Ltd, its second debt infusion in four months after a $7 million investment in March this year.
The proceeds from this funding will be used for business operations, development, and lending to subsidiaries outside India, the filing added.
Co-Founder and CEO Mudit Dandwate
VentriJect Raises €1.7M for Fitness Monitoring Expansion
Copenhagen-based VentriJect, a MedTech startup, recently raised €1.7 million in a funding round. Existing investors primarily led this investment, joined by the Export and Investment Fund of Denmark (EIFO), TechStation | HardTech Innovation Hub, Investo Capital, and private investor Carsten Stendevad.
This VentriJect raise supports the company’s expansion of its cardiorespiratory fitness monitoring device.
CEO Mikkel Kristiansen
Better Medicine raises €1 million to expand AI model for kidney cancer detection
Better Medicine has raised €1 million in a pre-Seed funding round to expand in Europe, prepare for U.S. entry, and pursue clinical and insurance partnerships. The round was led by Soulmates Ventures, with participation from Specialist VC, UT Ventures, and several angel investors.
In total, with additional grants, Better Medicine has now secured €2.25 million in private funding and €3.7 million in total grants, bringing its overall funding to nearly €6 million.
Founder and CEO Priit Salumaa
RIVANNA secures $800,000 Virginia Catalyst Grant alongside matching funds
RIVANNA, developers of world-first imaging-based medical technologies, was recently awarded grant funding valued at $800,000 from the Virginia Catalyst Program to advance the Accuro 3S diagnostic ultrasound system.
The Virginia Catalyst grant funding has been matched by $1.6 million in additional funding provided to RIVANNA from undisclosed sources, highlighting the clinical and economic potential of this initiative.
Co-Founder and CEO Will Mauldin
